CCM
BBOT

Catalio Capital Management’s BridgeBio Oncology BBOT Stock Holding History

Catalio Capital Management’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.43M Buy
+318,407
New +$2.66M 0.46% 33

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Catalio Capital Management's BBOT Position: Q2 2026 in Review

Catalio Capital Management opened a new position in BridgeBio Oncology (BBOT) in Q2 2026: 318,407 shares worth $2.43M. The stake represents 0.46% of the portfolio and ranks #33 among its holdings.

66 funds tracked by Wall St. Rank hold BBOT as of Q2 2026.

  • Catalio Capital Management held 318,407 shares of BridgeBio Oncology worth $2.43M as of Q2 2026.
  • BridgeBio Oncology was a new Catalio Capital Management position in Q2 2026.
  • BridgeBio Oncology made up 0.46% of Catalio Capital Management's portfolio in Q2 2026, its #33 holding.
  • 66 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q2 2026.

Based on Catalio Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.